In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Vivani Medical (VANI – Research Report), with a price target of $8.00.
Naz Rahman has given his Buy rating due to a combination of factors related to Vivani Medical’s innovative approach and promising developments. The company is advancing its NanoPortal drug delivery platform, which is designed to improve patient compliance in treating metabolic diseases such as obesity and diabetes. The recent successful implantation of NPM-115 in the Phase 1 LIBERATE-1 study marks a significant milestone, with the study fully enrolled and topline results anticipated in mid-2025.
Rahman highlights the growing market for GLP-1 and obesity treatments, noting that Vivani’s extended duration platform has the potential to address patient adherence issues, thereby enhancing clinical and commercial outcomes. The LIBERATE-1 study is primarily focused on evaluating the safety, tolerability, and pharmacokinetic profile of NPM-115, with weight loss as a secondary measure. This strategic focus on ensuring the implant functions as intended positions Vivani well in a competitive landscape, supporting the Buy rating.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.